Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 3989

Drug Profile

JNJ 3989

Alternative Names: ARO-HBV; JNJ-3989; JNJ-73763989

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Arrowhead Pharmaceuticals; Janssen Pharmaceuticals
  • Class Antivirals; Hepatoprotectants; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 17 Oct 2019 Janssen Research & Development plans a phase II trial for Hepatitis B (Combination therapy) in Belgium, France, Germany, Italy, Poland, Spain and United Kingdom in November 2019 (SC, Injection) (NCT04129554)
  • 23 Aug 2019 Janssen completes a phase I trial in Hepatitis B (In volunteers) in United Kingdom (NCT04002752)
  • 09 Aug 2019 Johnson & Johnson plans phase IIb trials in Hepatitis B, in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top